{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:15:30Z","timestamp":1791908130372,"version":"4.3.4"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.diabres.2023.110770","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T17:31:33Z","timestamp":1685899893000},"page":"110770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Perspectives on weight control in diabetes \u2013 Tirzepatide"],"prefix":"10.1016","volume":"202","author":[{"given":"Tam\u00e1s T.","family":"V\u00e1rkonyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik\u00f3","family":"P\u00f3sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"P\u00e1v\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Pavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2023.110770_b0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2023.110770_b0010","first-page":"23","article-title":"Tirzepatide: a systematic update","author":"Forzano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2023.110770_b0015","doi-asserted-by":"crossref","first-page":"1004044","DOI":"10.3389\/fendo.2022.1004044","article-title":"Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity","volume":"13","author":"Gallwitz","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0025","doi-asserted-by":"crossref","first-page":"1095753","DOI":"10.3389\/fendo.2023.1095753","article-title":"Effect of dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity","volume":"14","author":"Zaffina","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in Type 2 diabetes and obesity management","volume":"32","author":"Sinha","year":"2023","journal-title":"J. Obesity Metabolic Syndrome"},{"key":"10.1016\/j.diabres.2023.110770_b0035","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110770_b0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110770_b0045","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110770_b0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110770_b0055","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110770_b0060","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2023.110770_b0065","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2023.110770_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109118","article-title":"IDF diabetes Atlas: global estimates of undiagnosed diabetes in adults for 2021","volume":"183","author":"Ogurtsova","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2023.110770_b0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJM199908053410607","article-title":"Guidelines for healthy weight","volume":"341","author":"Willett","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110770_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110646","article-title":"Weight variability and diabetes complications","volume":"199","author":"Prattichizzo","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2023.110770_b0090","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwad072","article-title":"Risk factors variability and cardiovascular risk among patients with diabetes: a nationwide observational study","author":"Ceriello","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.diabres.2023.110770_b0095","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.clnu.2004.06.004","article-title":"Bioelectrical impedance analysis\u2013part I: review of principles and methods","volume":"23","author":"Kyle","year":"2004","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"key":"10.1016\/j.diabres.2023.110770_b0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1467-789x.2000.00013.x","article-title":"Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'?","volume":"1","author":"Astrup","year":"2000","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabres.2023.110770_b0105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","article-title":"Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity","volume":"3","author":"Khan","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabres.2023.110770_b0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.diabres.2023.110770_b0115","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","article-title":"Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease","volume":"71","author":"Rosso","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2023.110770_b0120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2337\/diacare.21.5.687","article-title":"The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM","volume":"21","author":"Markovic","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110770_b0125","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/dme.12722","article-title":"Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes","volume":"32","author":"Steven","year":"2015","journal-title":"Diabetic Med: A J Brit Diabetic Assoc"},{"issue":"45","key":"10.1016\/j.diabres.2023.110770_b0130","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"2022","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110770_b0135","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0140","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110770_b0145","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM199508313330903","article-title":"Metabolic effects of metformin in non-insulin-dependent diabetes mellitus","volume":"333","author":"Stumvoll","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110770_b0150","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110770_b0155","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1210\/jc.2002-021786","article-title":"Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes","volume":"88","author":"Pavo","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0160","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110770_b0165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","article-title":"Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus","volume":"169","author":"Kooy","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabres.2023.110770_b0170","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis","volume":"23","author":"Tsapas","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0175","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for Type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2023.110770_b0180","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.diabres.2023.110770_b0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2213-8587(21)00245-X","article-title":"Glycaemic management in diabetes: old and new approaches","volume":"10","author":"Ceriello","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0190","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0195","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How May GIP Enhance the Therapeutic Efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110770_b0205","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110770_b0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2023.110770_b0215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"Hojberg","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110770_b0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dom.13034","article-title":"A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents","volume":"20","author":"Norregaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2016.06.021","article-title":"Unimolecular Polypharmacy for Treatment of Diabetes and Obesity","volume":"24","author":"Tschop","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0230","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2023.110770_b0235","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s00125-007-0710-4","article-title":"Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets","volume":"50","author":"Gault","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110770_b0240","doi-asserted-by":"crossref","first-page":"e40156","DOI":"10.1371\/journal.pone.0040156","article-title":"GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.diabres.2023.110770_b0245","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170194","article-title":"The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system","volume":"125","author":"Adriaenssens","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.diabres.2023.110770_b0255","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-Dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0260","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbrc.2017.06.031","article-title":"Central administration of GLP-1 and GIP decreases feeding in mice","volume":"490","author":"NamKoong","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.diabres.2023.110770_b0265","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0270","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.regpep.2007.02.006","article-title":"GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women","volume":"142","author":"Rudovich","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.diabres.2023.110770_b0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2019.08.006","article-title":"Physiological roles of the GIP receptor in murine brown adipose tissue","volume":"28","author":"Beaudry","year":"2019","journal-title":"Molecular metabolism"},{"key":"10.1016\/j.diabres.2023.110770_b0280","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1053\/j.gastro.2007.09.005","article-title":"Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation","volume":"133","author":"Song","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2023.110770_b0285","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M609088200","article-title":"Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade","volume":"282","author":"Kim","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabres.2023.110770_b0290","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2023.110770_b0295","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/dc19-0578","article-title":"No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon-like peptide 1 receptor agonist in men with Type 2 diabetes","volume":"43","author":"Bergmann","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110770_b0300","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","article-title":"Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: a randomised, crossover study","volume":"62","author":"Bergmann","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110770_b0305","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.diabres.2023.110770_b0310","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with Type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2007.07.002","article-title":"The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance","volume":"144","author":"Knop","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.diabres.2023.110770_b0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0325","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110770_b0330","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0335","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/dom.14775","article-title":"Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison","volume":"24","author":"Vadher","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0340","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0345","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110770_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110271","article-title":"IDF2022-0369 Predictors of achieving weight loss \u226515% with tirzepatide in people with type 2 diabetes from SURPASS 1\u20134","volume":"197","author":"Malecki","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2023.110770_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110303","article-title":"IDF2022-0370 Characterization of tirzepatide-treated patients achieving different categorical measures of weight loss in SURPASS 1\u20134","volume":"197","author":"Batterham","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2023.110770_b0360","doi-asserted-by":"crossref","first-page":"729 -P","DOI":"10.2337\/db22-729-P","article-title":"729-P: Relationship between Body Weight Change and Glycemic Control with Tirzepatide Treatment in People with Type 2 Diabetes","volume":"71","author":"Pedersen","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2023.110770_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101261","article-title":"Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street","volume":"52","author":"White","year":"2021","journal-title":"Molecular metabolism"},{"key":"10.1016\/j.diabres.2023.110770_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101550","article-title":"Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue","volume":"64","author":"Samms","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0375","doi-asserted-by":"crossref","first-page":"714 -P","DOI":"10.2337\/db22-714-P","article-title":"714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism","volume":"71","author":"Mather","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2023.110770_b0380","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0385","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2018-02685","article-title":"Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide","author":"Fonseca","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0390","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes","volume":"107","author":"Pirro","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0395","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/dom.14174","article-title":"The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes","volume":"22","author":"Wilson","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110770_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110401","article-title":"IDF2022-0918 Tirzepatide reduces serum triglyceride irrespective of fibrate use in people with T2D at high CV risk (SURPASS-4)","volume":"197","author":"Kahn","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2023.110770_b0405","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","article-title":"Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","volume":"22","author":"Lingvay","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2023.110770_b0410","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0415","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110770_b0420","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.trsl.2017.01.001","article-title":"Cardiovascular consequences of metabolic syndrome","volume":"183","author":"Tune","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.diabres.2023.110770_b0425","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0735-1097(23)02072-7","article-title":"Compared to Insulin Glargine, Tirzepatide Reduces the Prevalence of the Metabolic Syndrome in Patients with Type 2 Diabetes and High Cardiovascular Risk: Post-hoc Analysis of SURPASS-4","volume":"81","author":"Nicholls Stephen","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2023.110770_b0430","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0435","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2023.110770_b0440","doi-asserted-by":"crossref","first-page":"10","DOI":"10.17925\/EE.2022.18.1.10","article-title":"Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes","volume":"18","author":"Kaneko","year":"2022","journal-title":"TouchREVIEWS Endocrinol"},{"key":"10.1016\/j.diabres.2023.110770_b0445","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12933-022-01601-w","article-title":"Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes","volume":"21","author":"McGuire","year":"2022","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723005338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723005338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:25:28Z","timestamp":1759173928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723005338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":89,"alternative-id":["S0168822723005338"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110770","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives on weight control in diabetes \u2013 Tirzepatide","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110770"}}